INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Cardiology / Health Desk

Cocoa and vascular function: a short-trial signal with limits

A review found improved flow-mediated dilatation, but the evidence was low to moderate in quality.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

What the review pooled

This review brought together 42 randomized controlled trials involving 1,297 participants. The interventions included chocolate, cocoa and flavan-3-ols; the trials were either acute experiments or short-term studies lasting no more than 18 weeks. That mixture matters when translating the headline into food choices. A cocoa-containing whole-food dessert is not automatically equivalent to the products or compounds studied. The review examined cardiovascular risk factors rather than reporting a reduction in heart attacks. Its findings belong to the specific measurements and short observation periods in the abstract, not to an assumed long-term benefit from any chocolate product.

Hooper L, Kay C, Abdelhamid A, Kroon PA et al.. The American journal of clinical nutrition, 2012. PMID 22301923 · DOI

The clearest vascular measurement

Flow-mediated dilatation, abbreviated FMD, improved after both acute and longer repeated intakes. The reported chronic effect was 1.34%, with a 95% confidence interval from 1.00% to 1.68%; the acute effect was 3.19%, with an interval from 2.04% to 4.33%. These figures describe the FMD endpoint, not percentages of cardiovascular events prevented. The FMD findings remained stable in sensitivity analyses. Even so, an acute response and a response during a study of at most 18 weeks should not be stretched into a claim about permanent vascular change or a guaranteed clinical outcome years later.

Hooper L, Kay C, Abdelhamid A, Kroon PA et al.. The American journal of clinical nutrition, 2012. PMID 22301923 · DOI

Other markers need their own labels

The review also reported a HOMA-IR difference of minus 0.67, with a 95% confidence interval from minus 0.98 to minus 0.36, and linked that improvement to lower serum insulin. Diastolic blood pressure fell by 1.60 mm Hg on average. The cholesterol findings were described as marginally significant: LDL differed by minus 0.07 mmol/L and HDL by plus 0.03 mmol/L, with confidence intervals reaching zero. These results should not be flattened into an equally strong claim for every cardiovascular marker. The abstract distinguishes more consistent FMD and insulin findings from less clear lipid effects.

Hooper L, Kay C, Abdelhamid A, Kroon PA et al.. The American journal of clinical nutrition, 2012. PMID 22301923 · DOI

Why the authors wanted better trials

Using GRADE, the reviewers judged the evidence low to moderate in quality. They identified unclear reporting of allocation concealment, dropouts and missing outcome data, as well as heterogeneity in some biomarker results. They also called for larger, longer-duration and independently funded trials. That request should not be recast as proof that every included study had a particular funding source; the abstract does not provide that breakdown. The appropriate reading is promising short-term marker evidence with methodological limits. Neither the review nor a cocoa recipe paired with it establishes long-term cardiovascular prevention or a personal cocoa dosing plan.

Hooper L, Kay C, Abdelhamid A, Kroon PA et al.. The American journal of clinical nutrition, 2012. PMID 22301923 · DOI